Search Results

4.Preoperative treatment of acromegaly with long-acting somatostatin analog octreotide.

Seok In LEE ; Hyun Kyu KIM ; Kyung Soo KO ; Kyong Soo PARK ; Seong Yeon KIM ; Bo Youn CHO ; Hong Kyu LEE ; Chang Soon KOH ; Hun Ki MIN ; Hyun Jip KIM ; Heu Won JEONG ; Dae Hee HAN

Journal of Korean Society of Endocrinology 1993;8(1):35-41

5.A focal form of diazoxide-resistant congenital hyperinsulinism with good response to long-acting somatostatin

Suhaimi Hussain ; Nurshafinaz Salmah Mohd Fezal ; Sarah Flanagan

Journal of the ASEAN Federation of Endocrine Societies 2024;39(2):108-111

6.Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors

Keunyoung KIM ; Seong Jang KIM

Nuclear Medicine and Molecular Imaging 2018;52(3):208-215

Peptide receptor radionuclide therapy (PRRT) is a systemic cytotoxic radiation therapy using a compound of β-emitting radionuclide chelated to a peptide for the treatment of tumor with overexpressed specific cell receptor such as somatostatin receptor subtype 2 (SSTR2) of neuroendocrine tumor (NET). Surgical resection should be performed for the curative treatment for NETs when it is feasible; however, a multi-disciplinary approach is needed when locally advanced or metastasized disease. PRRT with lutetium-177 (Lu-177)-labeled somatostatin analogues, as a new treatment modality targeting metastatic or inoperable NETs expressing the SSTR2, have been developed and successfully used for the past two decades. As Lu-177 emits both β- and γ-radiation, it has the ability as a theragnostic agent for NETs compared with only β-emitting yttrium-90 labeled PRRT. Several recent studies reported that Lu-177 gave an overall positive response and improved the patients' quality of life. To fully exploit its potential, large comparative studies are needed for the assessment of distinct efficacies of Lu-177 labeled PRRT. Additionally, for extending the indications and developing new regimens of Lu-177-based PRRT, more dedicated clinical research is required.
Neuroendocrine Tumors ; Quality of Life ; Receptors, Peptide ; Receptors, Somatostatin ; Somatostatin

7.Response: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010).

Seul Young KIM ; Dohee KIM

Endocrinology and Metabolism 2010;25(2):159-160

8.Letter: Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients (J Korean Endocr Soc 25:37-45, 2010).

Yu Bae AHN

Endocrinology and Metabolism 2010;25(2):157-158

9.Immunohistochemical localization of somatostatin in the midbrain periaqueductal gray of the Korean native goat.

In Se LEE ; Heung Shik LEE ; Seong Joon YI

Korean Journal of Anatomy 1993;26(3):326-337

10.Effects of glucose, insulin and somatostatin on collagen production by glomerular mesangial cell.

Chun Gyoo IHM ; Jae Kyung PARK ; Jae Hyung AHN ; Tae Won LEE ; Myung Jae KIM

Korean Journal of Nephrology 1992;11(3):200-206

1.Long-acting Somatostatin Analogues.

2.Somatostatin Receptor.

3.Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors.